Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 4,225 matching trials from the local directory fallback.

Filters: Intervention: Placebo Clear all

Conditions: Depression
Interventions: Placebo, Visbiome; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 24 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Genitourinary Cancer, Gynecologic Cancer, Head and Neck Cancer, Hodgkin Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Lymphoid Leukemia, Melanoma, Mycosis Fungoides, Myeloma Multiple, Non-hodgkin Lymphoma, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, Sarcoma, Urinary Bladder Cancer
Interventions: Placebo, Riluzole; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Hemiparesis, Stroke
Interventions: Active rTMS, Open Placebo, Sham rTMS; Device · Dietary Supplement
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Biospecimen Collection, Broccoli Sprout/Broccoli Seed Extract Supplement, Placebo Administration, Questionnaire Administration; Procedure · Dietary Supplement · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Buffalo, New York

Conditions: HIV Infections
Interventions: Midazolam, Placebo, VH4770359; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Achondroplasia
Interventions: Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration; Drug
Lead sponsor: QED Therapeutics, a BridgeBio company; Industry
Eligibility: 0 Years to 32 Months
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Oakland, California • Baltimore, Maryland • Madison, Wisconsin

Conditions: Ketone Monoester, Placebo - Control
Interventions: Ketone Monoester (KE), Placebo; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Migraine
Interventions: Placebo, Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Alzheimer Disease
Interventions: Lemborexant 10 mg, Lemborexant 20mg, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 65 Years and older
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions: Inhaled Treprostinil, Placebo, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 74
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 60 more

Conditions: IC-MPGN
Interventions: Placebo, iptacopan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 60 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: Los Angeles, California • Orange, California • San Francisco, California + 18 more

Conditions: Atrial Fibrillation (AF)
Interventions: Abelacimab, Placebo; Biological · Drug
Lead sponsor: Anthos Therapeutics, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 174
States / cities: Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 143 more

Conditions: Alzheimer Disease, Sleep
Interventions: Placebo, Suvorexant 20 mg; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 65 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Alzheimer Disease, Memory Impairment, Mild Cognitive Impairment
Interventions: CORT108297, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 55 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson's Disease (PD)
Interventions: EC5026 oral tablet, Placebo; Drug
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Erectile Dysfunction, Prostate Cancer
Interventions: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in clinic, Placebo in the OR; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Degenerative Disc Disease, Neuropathic Pain, Spinal Cord Injuries, Spinal Stenosis, Spondylosis
Interventions: EC5026 oral tablet, Placebo oral tablet; Drug
Lead sponsor: EicOsis Human Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Heart Failure
Interventions: Finerenone, Placebo; Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 18 Years and older
Enrollment: 2,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 54
States / cities: Fairhope, Alabama • Phoenix, Arizona • Yuma, Arizona + 45 more

Conditions: Hyperglycemia, Prediabetic State
Interventions: Placebo, Zinc Gluconate 30 MG; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Alzheimer's Disease, Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
Interventions: ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 at Dose C in Study Part 2, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b, Placebo (Study Part 1a), Placebo (Study Part 1b), Placebo (Study Part 2); Biological
Lead sponsor: AC Immune SA; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 13
States / cities: Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more

Conditions: Obstructive Sleep Apnea
Interventions: Atomoxetine Oral Capsule [Strattera], Placebo oral capsule; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sleep Disorders in Children
Interventions: Melatonin, Placebo; Dietary Supplement · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 13 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Loma Linda, California

Conditions: Psoriasis
Interventions: D-2570 Tablet, Placebo Tablets; Drug
Lead sponsor: InventisBio Co., Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 16 more

Conditions: Knee Osteoarthritis (OA), Obesity
Interventions: NNC0487-0111, Placebo (matched to NNC0487-0111 ); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Walnut Creek, California • Hamden, Connecticut + 16 more

Search by objective public record fields.

Probiotic Administration for Adolescent Depression

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Mechanisms of Open and Hidden Placebo in Stroke Recovery

Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)

The Effects of Exogenous Ketones on Cognitive Function

Mechanistic Studies of Psilocybin in Headache Disorders

DORA and LP in Alzheimer's Disease Biomarkers

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Sleep Trial to Prevent Alzheimer's Disease

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)

Stem Cells for Erectile Dysfunction Post RALP

Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord Injury

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Effect of Zinc on Glucose Homeostasis

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Atomoxetine and DAW2022 on OSA Severity

Melatonin Adolescent Research Study

A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain